Financial Performance Aligns with Analyst Projections Despite Revenue Dip
CRISPR Therapeutics (CRSP) reports mixed earnings results for first-quarter 2024. Management claims that the commercial launch for the first ever CRISPR-based gene therapy is progressing well.
As you might know, Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX ) just kicked off its latest quarterly results...